We are excited to announce the Weill Cornell Medical College Breast Center’s contributions to the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting next week!
Dr. Eleni Nackos (on behalf of Dr. Linda Vahdat) will be giving an oral presentation on the results from our phase 2 tetrathiomolybdate (TM) study. http://abstracts.asco.org/156/AbstView_156_151971.html
Dr. Tessa Cigler is chairing the Patient and Survivor Care session. Our abstract on cold caps was selected for a poster discussion session. http://abstracts.asco.org/156/AbstView_156_149240.html
Dr. Eleni Andreopoulou was selected by the International Development and Education Award (IDEA) group to mentor a physician from Morocco. Oncologists are selected by this group to host recipients for three-day visits following the ASCO meeting.
“The purpose of the IDEA program is to support the professional development of early-career oncologists in low- and middle-income countries around the world. The program pairs IDEA recipients with ASCO members in the United States or Canada who serve as their scientific mentors. Upon the mentees’ return to their home institution, it is expected that mentors and mentees remain in contact and pursue opportunities for consultation and collaboration.”
Dr. Anne Moore is chairing the Leadership Development Program presentation to the ASCO Board of Directors. The Leadership Development Program is a year-long program to learn leadership skills, gain exposure to the roles and mission of ASCO, and developing the future of cancer care. Dr. Moore is also joining the IDEA Working Group.
To view other abstracts from our studies:
PARP inhibitor ABT-888 http://abstracts.asco.org/156/AbstView_156_144933.html
Ovarian reserve and menses http://abstracts.asco.org/156/AbstView_156_147965.html
The METRIC study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150265.html
IMMU study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150673.html
Please find us on Twitter @CornellBreastCr & Facebook Weill Cornell Breast Center
Dr. Tessa Cigler, a Weill Cornell oncologist involved in the cold-cap studies, said she first learned about cold caps from a patient who had researched the treatment and learned about their use in Europe. After studying the European data on cold-cap treatment, she allowed her patient to use them and became interested in conducting her own research.
The success of a cold cap treatment often depends on the duration and type of chemotherapy regimen, so not every woman is a candidate, Dr. Cigler says. In addition, cold caps are typically used only on patients with solid tumors, like breast cancer, and are not suitable for patients with blood cancers.
“Cold cap therapy is really empowering to many patients,” Dr. Cigler said. “It has allowed many patients to protect their privacy, and allows women to maintain their self-esteem and their sense of well-being during a really difficult time.”
Dr. Linda Vahdat and her colleagues are very excited to be involved in the development of glembatumuma vedotin as it has the potential to be among the very first drugs for triple negative breast cancer.
The Weill Cornell Breast Center recently opened a new triple negative breast cancer program. The study is for women diagnosed with triple negative breast cancer. There is an urgent need to develop new, targeted treatments for triple negative breast cancer. Through our Program, we plan to integrate research, treatment and education to accelerate and identify new targets and strategies to treat and cure triple negative breast cancer.
For more information about the study, please call Margie for a consult appointment with Dr. Vahdat at (212)-821-0644 and contact Naomi for more information at (212)-821-0984 or email@example.com.
“From a patient perspective this study requires very little of participants. I think that for post-treatment women like me the opportunity to participate so easily in cutting edge research at a world-class institution like WCMC is a great way to ‘pay it forward’ in appreciation to all those women whose participation in past clinical trials directly benefited us in terms of improvements in how breast cancer is treated. This is an exceedingly rare opportunity!”
– Triple Negative Breast Cancer Program participant
MasterCard has announced a $500,000 grant to Weill Cornell Medical College to support women’s cancer research.
The grant will be used to to start or continue scientific investigations in developing breakthrough therapies in a variety of women’s cancers including breast, ovarian, and uterine cancer.
Click here to read the press release.
Dr. Linda Vahdat, director of the Weill Cornell Breast Center Research Program and Chief of the Solid Tumor Service at Weill Cornell, will be presenting a metastatic breast cancer research update for Living Beyond Breast Cancer’s free webinar on
Wednesday, October 16th from 12 noon to 1 pm.
In the webinar, Dr. Vahdat will help viewers explore:
- the latest clinical trial findings and their impact on today’s available treatment options
- novel therapies in the research pipeline and the role they may play in future care
- the latest understanding of what may cause metastasis and how we might prevent it in the future
Click here for more information about the free webinar. Click here to register for the webinar.
The Weill Cornell Breast Center has recently opened a new cold cap research study. The study is for women with early stage breast cancer who will be receiving chemotherapy that has a high probability of causing them to lose their hair.
The study sponsor is Dignitana, and the principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at firstname.lastname@example.org.
Women age 18 and older
Stage I or II breast cancer
Planned course of chemotherapy in the adjuvant or neoadjuvant setting
Plan to complete chemotherapy within 6 months
Detailed eligibility reviewed when you contact the study team
The purpose of the study is to evaluate the safety and effectiveness of an experimental medical device called the DigniCap System, a cooling system designed to help prevent chemotherapy-induced hair loss. Scalp cooling works by constricting the small blood vessels around the hair follicles so that less chemotherapy reaches the follicle. Hair cells are therefore not exposed to the full dose of chemotherapy and survive the chemotherapy treatment. As a result, hair is less likely to be lost.
Study participants will wear the DigniCap cooling cap on their head for 30 minutes before starting a chemotherapy treatment, during the chemotherapy infusion and for up to 90 minutes after the infusion is finished. Participants will wear the cap for three to six hours during each chemotherapy treatment, depending on the chemotherapy regimen.
Participants will be photographed as part of the research study to assess hair loss. Participants will be seen 4 weeks after their final chemotherapy cycle, and then 3 and 6 months later for follow-up.
Click here to view all current clinical trials at the Breast Center.
A recent Associated Press article discussed research on cold caps taking place at various research centers throughout the United States, including the Weill Cornell Breast Center. Click here to read the article.
The Weill Cornell Breast Center has an ongoing, investigator-initiated cold caps clinical trial led by Dr. Tessa Cigler. Click here to view Dr. Cigler discussing cold caps on WABC news.
Dr. Anne Moore
Dr. Anne Moore, the Medical Director of the Weill Cornell Breast Center, will be the featured speaker at the Cancer Support Team‘s 15th annual Gayle K. Lee Women’s Health Awareness Luncheon on Thursday, October 10th, 2013 at the Westchester Country Club.
For more information, please call 914-777-2777.